Effect of baseline glycosylated hemoglobin a1c on glycemic control and diabetes management following initiation of once-daily insulin detemir in real-life clinical practice

Salvatore Caputo, Henning Andersen, Marcel Kaiser, Eddy Karnieli, Luigi F. Meneghini, Anne Louise Svendsen

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: The SOLVE study investigate. The initiation of basal insulin in patients with type 2 diabetes on oral antidiabetic (OAD) treatment and outcomes in patients with varying levels of glycemic control at baseline.Methods: This was an observational cohort study conducted in 10 countries using insulin detemir. Data were collected at 3 clinic visits (baseline, 12-week interim, and 24-week final visit).Results: A total of 13,526 (77.9%) patients were included i. The glycosylated hemoglobin A1c (HbA1c) subset analysis. Patients were grouped according to pre-insulin HbA1c values as follows: HbA1c <7.6% (n = 2,797); HbA1c 7.6-9% (n = 5,366), and HbA1c >9% (n = 5,363). A total of 27 patients experienced serious adverse drug reactions (SADRs) and/or severe hypoglycemia (3, 10, and 11 patients with pre-insulin HbA1c <7.6%, 7.6-9.0%, and >9.0%, respectively). All patient subgroups realized improvements in HbA1c, wit. The pre-insulin HbA1c >9% subgroup havin. The largest HbA1c reduction (-2.4% versus -0.9% and -0.2% for HbA1c subgroups 7.6-9% and <7.6%, respectively). I. The total cohort (n = 17,374). The incidence of severe hypoglycemia decreased from 4 events per 100 person years to <1 event per 100 person years by final visit. The incidence of minor hypoglycemia increased from 1.6 to 1.8 events per person year.Conclusions: In this study, insulin initiation was delayed until late in disease course, and overall concordance with internationally recognized guidelines was low. The initiation of once-daily insulin detemir was associated with substantial improvements in glycemic control and was not associated with an increase in severe hypoglycemia or weight gain.

Original languageEnglish
Pages (from-to)462-470
Number of pages9
JournalEndocrine Practice
Volume19
Issue number3
DOIs
StatePublished - May 1 2013

Fingerprint

Glycosylated Hemoglobin A
Hemoglobins
Hypoglycemia
Insulin
Wit and Humor
Incidence
Ambulatory Care
Insulin Detemir
Drug-Related Side Effects and Adverse Reactions
Hypoglycemic Agents
Type 2 Diabetes Mellitus
Weight Gain
Observational Studies
Cohort Studies
Guidelines

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Effect of baseline glycosylated hemoglobin a1c on glycemic control and diabetes management following initiation of once-daily insulin detemir in real-life clinical practice. / Caputo, Salvatore; Andersen, Henning; Kaiser, Marcel; Karnieli, Eddy; Meneghini, Luigi F.; Svendsen, Anne Louise.

In: Endocrine Practice, Vol. 19, No. 3, 01.05.2013, p. 462-470.

Research output: Contribution to journalArticle

Caputo, Salvatore ; Andersen, Henning ; Kaiser, Marcel ; Karnieli, Eddy ; Meneghini, Luigi F. ; Svendsen, Anne Louise. / Effect of baseline glycosylated hemoglobin a1c on glycemic control and diabetes management following initiation of once-daily insulin detemir in real-life clinical practice. In: Endocrine Practice. 2013 ; Vol. 19, No. 3. pp. 462-470.
@article{72be1c33b43f43b3b4b5e6bf49bb56e9,
title = "Effect of baseline glycosylated hemoglobin a1c on glycemic control and diabetes management following initiation of once-daily insulin detemir in real-life clinical practice",
abstract = "Objective: The SOLVE study investigate. The initiation of basal insulin in patients with type 2 diabetes on oral antidiabetic (OAD) treatment and outcomes in patients with varying levels of glycemic control at baseline.Methods: This was an observational cohort study conducted in 10 countries using insulin detemir. Data were collected at 3 clinic visits (baseline, 12-week interim, and 24-week final visit).Results: A total of 13,526 (77.9{\%}) patients were included i. The glycosylated hemoglobin A1c (HbA1c) subset analysis. Patients were grouped according to pre-insulin HbA1c values as follows: HbA1c <7.6{\%} (n = 2,797); HbA1c 7.6-9{\%} (n = 5,366), and HbA1c >9{\%} (n = 5,363). A total of 27 patients experienced serious adverse drug reactions (SADRs) and/or severe hypoglycemia (3, 10, and 11 patients with pre-insulin HbA1c <7.6{\%}, 7.6-9.0{\%}, and >9.0{\%}, respectively). All patient subgroups realized improvements in HbA1c, wit. The pre-insulin HbA1c >9{\%} subgroup havin. The largest HbA1c reduction (-2.4{\%} versus -0.9{\%} and -0.2{\%} for HbA1c subgroups 7.6-9{\%} and <7.6{\%}, respectively). I. The total cohort (n = 17,374). The incidence of severe hypoglycemia decreased from 4 events per 100 person years to <1 event per 100 person years by final visit. The incidence of minor hypoglycemia increased from 1.6 to 1.8 events per person year.Conclusions: In this study, insulin initiation was delayed until late in disease course, and overall concordance with internationally recognized guidelines was low. The initiation of once-daily insulin detemir was associated with substantial improvements in glycemic control and was not associated with an increase in severe hypoglycemia or weight gain.",
author = "Salvatore Caputo and Henning Andersen and Marcel Kaiser and Eddy Karnieli and Meneghini, {Luigi F.} and Svendsen, {Anne Louise}",
year = "2013",
month = "5",
day = "1",
doi = "10.4158/EP12269.OR",
language = "English",
volume = "19",
pages = "462--470",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "3",

}

TY - JOUR

T1 - Effect of baseline glycosylated hemoglobin a1c on glycemic control and diabetes management following initiation of once-daily insulin detemir in real-life clinical practice

AU - Caputo, Salvatore

AU - Andersen, Henning

AU - Kaiser, Marcel

AU - Karnieli, Eddy

AU - Meneghini, Luigi F.

AU - Svendsen, Anne Louise

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Objective: The SOLVE study investigate. The initiation of basal insulin in patients with type 2 diabetes on oral antidiabetic (OAD) treatment and outcomes in patients with varying levels of glycemic control at baseline.Methods: This was an observational cohort study conducted in 10 countries using insulin detemir. Data were collected at 3 clinic visits (baseline, 12-week interim, and 24-week final visit).Results: A total of 13,526 (77.9%) patients were included i. The glycosylated hemoglobin A1c (HbA1c) subset analysis. Patients were grouped according to pre-insulin HbA1c values as follows: HbA1c <7.6% (n = 2,797); HbA1c 7.6-9% (n = 5,366), and HbA1c >9% (n = 5,363). A total of 27 patients experienced serious adverse drug reactions (SADRs) and/or severe hypoglycemia (3, 10, and 11 patients with pre-insulin HbA1c <7.6%, 7.6-9.0%, and >9.0%, respectively). All patient subgroups realized improvements in HbA1c, wit. The pre-insulin HbA1c >9% subgroup havin. The largest HbA1c reduction (-2.4% versus -0.9% and -0.2% for HbA1c subgroups 7.6-9% and <7.6%, respectively). I. The total cohort (n = 17,374). The incidence of severe hypoglycemia decreased from 4 events per 100 person years to <1 event per 100 person years by final visit. The incidence of minor hypoglycemia increased from 1.6 to 1.8 events per person year.Conclusions: In this study, insulin initiation was delayed until late in disease course, and overall concordance with internationally recognized guidelines was low. The initiation of once-daily insulin detemir was associated with substantial improvements in glycemic control and was not associated with an increase in severe hypoglycemia or weight gain.

AB - Objective: The SOLVE study investigate. The initiation of basal insulin in patients with type 2 diabetes on oral antidiabetic (OAD) treatment and outcomes in patients with varying levels of glycemic control at baseline.Methods: This was an observational cohort study conducted in 10 countries using insulin detemir. Data were collected at 3 clinic visits (baseline, 12-week interim, and 24-week final visit).Results: A total of 13,526 (77.9%) patients were included i. The glycosylated hemoglobin A1c (HbA1c) subset analysis. Patients were grouped according to pre-insulin HbA1c values as follows: HbA1c <7.6% (n = 2,797); HbA1c 7.6-9% (n = 5,366), and HbA1c >9% (n = 5,363). A total of 27 patients experienced serious adverse drug reactions (SADRs) and/or severe hypoglycemia (3, 10, and 11 patients with pre-insulin HbA1c <7.6%, 7.6-9.0%, and >9.0%, respectively). All patient subgroups realized improvements in HbA1c, wit. The pre-insulin HbA1c >9% subgroup havin. The largest HbA1c reduction (-2.4% versus -0.9% and -0.2% for HbA1c subgroups 7.6-9% and <7.6%, respectively). I. The total cohort (n = 17,374). The incidence of severe hypoglycemia decreased from 4 events per 100 person years to <1 event per 100 person years by final visit. The incidence of minor hypoglycemia increased from 1.6 to 1.8 events per person year.Conclusions: In this study, insulin initiation was delayed until late in disease course, and overall concordance with internationally recognized guidelines was low. The initiation of once-daily insulin detemir was associated with substantial improvements in glycemic control and was not associated with an increase in severe hypoglycemia or weight gain.

UR - http://www.scopus.com/inward/record.url?scp=84880117552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880117552&partnerID=8YFLogxK

U2 - 10.4158/EP12269.OR

DO - 10.4158/EP12269.OR

M3 - Article

C2 - 23337147

AN - SCOPUS:84880117552

VL - 19

SP - 462

EP - 470

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 3

ER -